Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 Combination Therapy in Advanced Solid Tumors
NCT05765032Phase 2Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tizetatug rezetecan in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Dec 2022; status: active, not recruiting.
02
Drugs
tizetatug rezetecan
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05765032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765032.